Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9): The Multifaceted Biology, Diseases, and Pharmaceutical Interventions
ABSTRACT Ischemic stroke remains a leading cause of global disability and death. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have emerged as potent lipid‐lowering agents with expanding therapeutic potential. Beyond robust low‐density lipoprotein cholesterol reduction, accumulati...
Guardado en:
| Autores principales: | , , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Wiley
2025-11-01
|
| Colección: | MedComm |
| Materias: | |
| Acceso en línea: | https://doi.org/10.1002/mco2.70451 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|